[Acceptability of the etonogestrel-containing contraceptive implant (Implanon)]. 2004

F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
Clinique Gynécologique et Obstétricale, Pavillon Mère-Enfant, Hôpital Charles Nicolle, 1, rue de Germont, 76031 Rouen Cedex. Fabrice.Sergent@chu-rouen.fr

OBJECTIVE To estimate the exact satisfaction of women toward Implanon, the sole contraceptive implant available in France. To clarify the indications of this type of contraception. METHODS Among a population of 182 women with Implanon" inserted in a same family planning service between May 22, 2001 and February 14, 2003, 108 women agreed to answer a questionnaire of satisfaction. Implants were inserted in one third of cases after childbirth, in another third after abortion. The average duration of use of the implant was of 16 months (2 in 24 months). Twenty-nine removals among the 108 insertions (27%) were recorded. RESULTS Possibility of a long-term and easy -to-use contraception was the most common reason for choosing Implanon (74% of the women). Eighty-one percent of the women were globally satisfied with Implanon but one out of two women had side-effects. Only 62% of the women were ready to use it again. Adverse events were first, menstrual disturbance in 83% of the women, mainly amenorrhea (26%) and bleeding irregularity (40%). Bleeding irregularity was one of the main motives for discontinuing the implant in 41% of cases. Except weight gain present for 37% of patients, the other side-effects, even though they were frequent, were less often the reason for removal. Headache, acne, breast pain, mood and decreased libido were the main reasons for removal. CONCLUSIONS Implanon has certainly a place among current contraceptive methods. Because of the frequency raised by adverse events and by their lower tolerance in Europe, this place has to remain limited to the incapacity of classic methods. Preinsertion counseling announcing Implanon's benefit and risk effects is necessary to minimize the early discontinuation rates.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D003271 Contraceptive Agents, Female Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading. Contraceptives, Female,Agents, Female Contraceptive,Female Contraceptive Agents,Female Contraceptives
D004343 Drug Implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug. Drug Implant,Drug Pellet,Pellets, Drug,Drug Pellets,Implant, Drug,Implants, Drug,Pellet, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000568 Amenorrhea Absence of menstruation. Postpartum Amenorrhea,Amenorrhea, Postpartum,Postpartum Amenorrheas
D014592 Uterine Hemorrhage Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding. Hemorrhage, Uterine,Vaginal Bleeding,Uterine Bleeding,Bleeding, Uterine,Bleeding, Vaginal,Bleedings, Vaginal,Uterine Bleedings,Uterine Hemorrhages,Vaginal Bleedings

Related Publications

F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
June 2001, Current opinion in obstetrics & gynecology,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
November 1998, Contraception,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
October 2005, Journal de gynecologie, obstetrique et biologie de la reproduction,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
September 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
April 2017, The journal of family planning and reproductive health care,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
September 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
August 2001, Drug and therapeutics bulletin,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
September 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
May 2005, Contraception,
F Sergent, and C Clamageran, and A-M Bastard, and E Verspyck, and L Marpeau
March 2009, Contraception,
Copied contents to your clipboard!